Allied Market Research

2025

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market, by Product Type (Targeted Drug Therapy, Immunotherapies, Conventional Chemotherapy, Hematopoietic Stem Cell Transplantation, Others), by Drug Class (Fludarabine-based, Anthracyclines, Cyclophosphamide-based, Others) and, by Route of Administration (Oral, Injectables, Others): Opportunity Analysis and Industry Forecast, 2023-2032

LS : Other

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

The global Acute myeloid leukemia market report covers market size, share, and growth rate (CAGR %) for various segments at regional and country levels. Along with various market dynamics such as drivers, restraints, market trends, and opportunities, the market overview section of the report highlights the qualitative aspect of the market. Furthermore, the section covers the market snapshot and key findings, in terms of investment opportunity and market overview. The report further includes a detailed competitive landscape comprising comprehensive profiles of leading players. The top players are assessed depending on their revenue size, market share, geographical presence, recent developments & strategic initiatives, and overall contribution to the market.

Key players identified in this report are Novartis AG, Janssen Biotech Inc., Pfizer, Inc., Hoffmann-La Roche Ltd., Roche Holding AG, Bristol-Myers Squibb, Amgen Inc., Teva Pharmaceuticals, Memorial Sloan Kettering Cancer Center, AstraZeneca Plc

Market Snapshot

Report Metric

Details

Market size available for the years

2032

Base year considered

2023

Forecast period

2024

Forecast unit

Value (USD)

Segments covered

by product type, by drug class, by route of administration

Companies covered

Novartis AG, Janssen Biotech Inc., Pfizer, Inc., Hoffmann-La Roche Ltd., Roche Holding AG, Bristol-Myers Squibb, Amgen Inc., Teva Pharmaceuticals, Memorial Sloan Kettering Cancer Center, AstraZeneca Plc

Key Inclusions

  • Qualitative as well as quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors

  • Analysis at regional and country level, which highlights the consumption of the product or service in the different geographies.

  • Extensive company profiles section, which includes different pointers such as company overview, key executive, company snapshot, business performance, product/service portfolio, R&D spending, and key strategies and developments of the major market players.

  • The current and estimated market outlook of the Acute myeloid leukemia market with respect to recent developments which include analysis of drivers, market trends, and growth opportunities

  • Free 20% customization and post-sales support

Acute Myeloid Leukemia Market, by Product Type Report Highlights

Aspects Details
icon_5
By Product Type
  • Targeted Drug Therapy
  • Immunotherapies
  • Conventional Chemotherapy
  • Hematopoietic Stem Cell Transplantation
  • Others
icon_6
By Drug Class
  • Fludarabine-based
  • Anthracyclines
  • Cyclophosphamide-based
  • Others
icon_7
By Route of Administration
  • Oral
  • Injectables
  • Others
icon_8
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
icon_9
Key Market Players

Hoffmann-La Roche Ltd., Pfizer, Memorial Sloan Kettering Cancer Center, Roche Holding AG, Janssen Biotech Inc., Bristol-Myers Squibb, AstraZeneca Plc, Novartis AG, Amgen Inc., Teva Pharmaceuticals

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Acute Myeloid Leukemia Market, by Product Type

Opportunity Analysis and Industry Forecast, 2023-2032